summit trial tirzepatide SUMMIT: a 'Huge Win' for HFpEF Patients With Obesity ๐ซ4th ACC.25 Congress Coverage: Tirzepatide
Pay in 4 interest-free payments of $5.61 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 1 - Aug 6
Live Spec
4th ACC.25 Congress Coverage: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity, SUMMIT Trial, by Dr. Roudbari, Cardiologist., Stay tuned for more insights from the Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial JACC Tirzepatide Shows Superior Weight Loss Over Semaglutide in Phase 3 Trial Drug Topics Tirzepatide made headlines for weight loss. But that's not why longevity doctors are paying attention. As a dual GIP GLP 1 receptor agonist, it works on pathways that go far beyond metabolism. The data JACC #ACC25: A recent #JACC publication on the SUMMIT trial evaluates tirzepatide in patients with #HFpEF, with secondary analyses focusing on (1) cardiac structure and (2) #CKD. https: bit.ly 3EdDCQK Facebook Tirzepatide: A Systematic Update
Store: jftbasic.com ยท Domain: jftbasic.com



























